Plus Therapeutics’ President & CEO, Marc Hedrick, M.D., was recently featured as a key opinion leader in a Nature Cancer article by Melanie Senior highlighting how biotechnology companies are advancing the next generation of radiopharmaceutical therapies ahead of major data readouts.
In the article, Dr. Hedrick discusses the promise of rhenium-186 nanoliposome technology (REYOBIQ™), a targeted radiotherapeutic being evaluated in Plus Therapeutics’ ReSPECT clinical trials.
“Plus Therapeutics is using rhenium-186, whose 90-hour half-life and 2- to 4-mm beta-radiation pathlength, plus gamma imaging rays, appear ideal for central nervous system cancers including invasive glioblastomas and leptomeningeal metastases, which can be diffuse and tricky to image…The nature of rhenium-186 radiation — with a longer path length than that of alpha emitters, but higher energy than the slower-decaying beta emitter lutetium — may help to overcome brain tissue’s high radioresistance.”
— Nature Cancer
The Science Behind REYOBIQ™ and the ReSPECT Clinical Program
Rhenium-186 is a beta-emitting radioisotope with a unique combination of therapeutic and imaging properties, making it especially suited for tumors that are difficult to reach or visualize — such as those in the central nervous system (CNS).
Through Plus Therapeutics’ proprietary nanoliposome delivery system, REYOBIQ™ is designed to:
-
Deliver radiation directly to the tumor site with sub-millimeter precision.
-
Reduce exposure to healthy brain tissue.
-
Enable imaging feedback to visualize drug distribution and optimize treatment planning.
These features are being studied in the ReSPECT-LM clinical trial for leptomeningeal metastases (LM) and the ReSPECT-GBM program for glioblastoma (GBM) — two of the most challenging CNS cancers with limited treatment options.
Why It Matters
Unlike traditional chemotherapy or external-beam radiation, targeted radiotherapeutics like REYOBIQ™ are designed to treat tumors from the inside out, leveraging precision physics and molecular targeting to deliver powerful, localized radiation while minimizing systemic side effects.
This approach represents a transformational advance in the treatment of CNS cancers — where drug delivery barriers, tumor heterogeneity, and imaging limitations have historically constrained progress.
Learn more about the science driving this innovation at https://plustherapeutics.com/radiotherapeutics.
Learn More and Get Involved
Read the full Nature Cancer article: https://lnkd.in/enzrbPne
Explore ReSPECT clinical trials: https://www.respect-trials.com
More about REYOBIQ™ and Plus Therapeutics’ radiotherapeutic platform: https://plustherapeutics.com/radiotherapeutics
Recent Comments